TSO3 Inc, a developer of sterilization technologies for medical devices, has signed its first commercial agreement with Getinge Infection Control to support the launch of the Sterizone VP4 Sterilization System. The nonexclusive deal covers multiple markets where Getinge has significant market share, including North America.
“We are extremely pleased to have Getinge Infection Control representing our Sterizone technology,” said R.M. (Ric) Rumble, president and CEO of TSO3 Inc. “Getinge has watched the progression of our technology through the US regulatory process and with US clearance now in hand, both organizations see the opportunity to launch this superior technology in North America and selected additional markets.”
Cleared for the United States market in December 2014, the Sterizone VP4 Sterilizer is a dual sterilant, low-temperature sterilization system that uses vaporized hydrogen peroxide and ozone to sterilize a large number and wide range of compatible devices. According to the company, the device’s 75-pound load and short cycle time can increase throughput and reduce sterilization costs.
“The TSO3 technology fills a gap in our portfolio and is a natural fit for our commercial team,” said Andrew Ray, president and CEO of Getinge Infection Control North America. “Our entire organization is anxious to get started assisting our mutual customers [in understanding] how this technology improves their process and reduces the cost of sterilization while improving patient outcomes.”
